479 related articles for article (PubMed ID: 21324923)
1. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
Fujita M; Kohanbash G; Fellows-Mayle W; Hamilton RL; Komohara Y; Decker SA; Ohlfest JR; Okada H
Cancer Res; 2011 Apr; 71(7):2664-74. PubMed ID: 21324923
[TBL] [Abstract][Full Text] [Related]
2. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
Kosaka A; Ohkuri T; Okada H
Cancer Immunol Immunother; 2014 Aug; 63(8):847-57. PubMed ID: 24878890
[TBL] [Abstract][Full Text] [Related]
3. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.
Obermajer N; Muthuswamy R; Odunsi K; Edwards RP; Kalinski P
Cancer Res; 2011 Dec; 71(24):7463-70. PubMed ID: 22025564
[TBL] [Abstract][Full Text] [Related]
4. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.
Veltman JD; Lambers ME; van Nimwegen M; Hendriks RW; Hoogsteden HC; Aerts JG; Hegmans JP
BMC Cancer; 2010 Aug; 10():464. PubMed ID: 20804550
[TBL] [Abstract][Full Text] [Related]
5. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.
Obermajer N; Muthuswamy R; Lesnock J; Edwards RP; Kalinski P
Blood; 2011 Nov; 118(20):5498-505. PubMed ID: 21972293
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice.
Shi M; Shi G; Tang J; Kong D; Bao Y; Xiao B; Zuo C; Wang T; Wang Q; Shen Y; Wang H; Funk CD; Zhou J; Yu Y
J Allergy Clin Immunol; 2014 Nov; 134(5):1163-74.e16. PubMed ID: 24948368
[TBL] [Abstract][Full Text] [Related]
7. Premetastatic soil and prevention of breast cancer brain metastasis.
Liu Y; Kosaka A; Ikeura M; Kohanbash G; Fellows-Mayle W; Snyder LA; Okada H
Neuro Oncol; 2013 Jul; 15(7):891-903. PubMed ID: 23595625
[TBL] [Abstract][Full Text] [Related]
8. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
Muthuswamy R; Corman JM; Dahl K; Chatta GS; Kalinski P
Prostate; 2016 Sep; 76(12):1095-105. PubMed ID: 27199259
[TBL] [Abstract][Full Text] [Related]
9. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
10. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Bronger H; Kraeft S; Schwarz-Boeger U; Cerny C; Stöckel A; Avril S; Kiechle M; Schmitt M
Breast Cancer Res; 2012 Feb; 14(1):R30. PubMed ID: 22333315
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of antitumor activity by combination of tumor lysate-pulsed dendritic cells and celecoxib in a rat glioma model.
Zhang H; Tian M; Xiu C; Wang Y; Tang G
Oncol Res; 2013; 20(10):447-55. PubMed ID: 24308155
[TBL] [Abstract][Full Text] [Related]
12. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Fink SP; Dawson DM; Zhang Y; Kresak A; Lawrence EG; Yang P; Chen Y; Barnholtz-Sloan JS; Willis JE; Kopelovich L; Markowitz SD
Carcinogenesis; 2015 Feb; 36(2):291-8. PubMed ID: 25503930
[TBL] [Abstract][Full Text] [Related]
13. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
14. Differential response of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory agent indomethacin in tumor-associated and tumor-free microenvironments.
Blidner AG; Salatino M; Mascanfroni ID; Diament MJ; Bal de Kier Joffé E; Jasnis MA; Klein SM; Rabinovich GA
J Immunol; 2015 Apr; 194(7):3452-62. PubMed ID: 25740944
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
16. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.
Fujita M; Scheurer ME; Decker SA; McDonald HA; Kohanbash G; Kastenhuber ER; Kato H; Bondy ML; Ohlfest JR; Okada H
Clin Cancer Res; 2010 Jul; 16(13):3409-19. PubMed ID: 20472682
[TBL] [Abstract][Full Text] [Related]
17. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.
Chang AL; Miska J; Wainwright DA; Dey M; Rivetta CV; Yu D; Kanojia D; Pituch KC; Qiao J; Pytel P; Han Y; Wu M; Zhang L; Horbinski CM; Ahmed AU; Lesniak MS
Cancer Res; 2016 Oct; 76(19):5671-5682. PubMed ID: 27530322
[TBL] [Abstract][Full Text] [Related]
18. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice.
Schmid M; Zimara N; Wege AK; Ritter U
Eur J Immunol; 2014 Nov; 44(11):3295-306. PubMed ID: 25142017
[TBL] [Abstract][Full Text] [Related]
20. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
